Posts

Neovascular Age-Related Macular Degeneration (nAMD) – Market Access and Reimbursement Insights Report – 2026

Neovascular Age-Related Macular Degeneration (nAMD) Market Access and Reimbursement Insights Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Access and Reimbursement Insights Report – 2026″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Neovascular Age-Related Macular Degeneration (nAMD) Overview Neovascular age-related macular degeneration (nAMD) is an advanced, exudative variant of macular degeneration characterized by choroidal neovascularization, where pathological vessels sprout from the choriocapillaris into the subretinal space. Driven by vascular endothelial growth factor (VEGF) upregulation, these leaky vessels cause subretinal hemorrhage, macular fluid...
Post a Comment
Read more

Acute Myeloid Leukemia (AML) – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden Thelansis’s “Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . ⁠ Acute Myeloid Leukemia (AML) Overview Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulation of immature blast cells in the bone marrow. Somatic mutations in FLT3, NPM1, IDH1, IDH2, and TP53 alongside ...
Post a Comment
Read more

Neovascular Age-Related Macular Degeneration (nAMD) – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . ⁠ Neovascular Age-Related Macular Degeneration (nAMD) Overview Neovascular age-related macular degeneration (nAMD) is an advanced, exudative retinal condition characterized by choroidal neovascularization sprouting into the subretinal space. Driven by VEGF upregulation, the...
Post a Comment
Read more

Bladder Cancer – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Bladder Cancer Epidemiology Insights Thelansis’s “Bladder Cancer Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . ⁠ Bladder Cancer Overview Bladder cancer is a common urothelial tract malignancy driven by risk factors like smoking and somatic mutations (FGFR3, TP53). Painless hematuria is the cardinal symptom, with diagnosis confirmed via cystoscopy and CT urography. The therapeutic landscape across all stages has been entirely transformed by immunotherapy and antibody-drug co...
Post a Comment
Read more

Acute Lymphoblastic Leukemia (ALL) – Epidemiology Insights and Disease Burden Report – 2020 To 2040

Acute Lymphoblastic Leukemia (ALL) Epidemiology Insights Thelansis’s “Acute Lymphoblastic Leukemia (ALL) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . ⁠ Acute Lymphoblastic Leukemia (ALL) Overview Acute lymphoblastic leukemia (ALL) is an aggressive malignancy of B- or T-cell precursors driven by aberrations like BCR-ABL1, KMT2A, or Ph-like signatures. Patients present with cytopenias, lymphadenopathy, and CNS involvement, with diagnosis established via flow cytometry and mo...
Post a Comment
Read more

Acute Myeloid Leukemia (AML) – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040

Acute Myeloid Leukemia (AML) Epidemiology Insights Thelansis’s “Acute Myeloid Leukemia (AML) Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America) . ⁠ Acute Myeloid Leukemia (AML) Overview Acute Myeloid Leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulat...
Post a Comment
Read more

Bladder Cancer – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040

  Bladder Cancer Epidemiology Insights Thelansis’s “Bladder Cancer Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America) . ⁠ Bladder Cancer Overview Bladder cancer is a common urothelial tract malignancy driven by risk factors like smoking and somatic mutations (FGFR3, TP53). Painless hematuria is the cardinal symptom, with diagno...
Post a Comment
Read more